Participant flow20

How many started, completed or left each group, period by period.

1 to 20 of 20

Period	Milestone	Group	Participants
Overall Study	STARTED	De Novo	86
Overall Study	STARTED	Rollover Placebo	70
Overall Study	STARTED	Rollover Aripiprazole	174
Overall Study	STARTED	Total	330
Overall Study	Safety Population	De Novo	86
Overall Study	Safety Population	Rollover Placebo	70
Overall Study	Safety Population	Rollover Aripiprazole	174
Overall Study	Safety Population	Total	330
Overall Study	Efficacy Population	De Novo	84
Overall Study	Efficacy Population	Rollover Placebo	69
Overall Study	Efficacy Population	Rollover Aripiprazole	169
Overall Study	Efficacy Population	Total	322
Overall Study	COMPLETED	De Novo	55
Overall Study	COMPLETED	Rollover Placebo	37
Overall Study	COMPLETED	Rollover Aripiprazole	107
Overall Study	COMPLETED	Total	199
Overall Study	NOT COMPLETED	De Novo	31
Overall Study	NOT COMPLETED	Rollover Placebo	33
Overall Study	NOT COMPLETED	Rollover Aripiprazole	67
Overall Study	NOT COMPLETED	Total	131

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00365859/flow